jsonp_parse_post_list([{"post_id":"v-69f70237-124f-3ea9-acd0-fc922af945e2_c-2c3ce34d-698e-321f-ae77-693f294820ff_a-6c27e4e8-d8d3-33b8-a6a3-b2791390854c","post_url":"https:\/\/www.yahoo.com\/newsroom\/vibes\/world-news\/fda-clears-pfizers-xeljanz-inflammatory-17u8gpk","author":"nanook","provider":"Reuters","provider_url":"http:\/\/www.reuters.com\/","provider_image":"http:\/\/media.zenfs.com\/284\/2011\/06\/21\/reuters-85x27_113626.gif","lead_attribution":"provider","link":"https:\/\/finance.yahoo.com\/news\/fda-clears-pfizers-xeljanz-inflammatory-163654202.html","imgresolutions":null,"img":null,"imgw":null,"imgh":null,"title":"FDA clears Pfizer's Xeljanz for inflammatory bowel disease","summary":"The U.S. Food and Drug Administration said on Wednesday that it had approved Pfizer Inc's drug, Xeljanz, to treat adults with moderate-to-severe active ulcerative colitis. The effectiveness of Xeljanz in treating ulcerative colitis was shown in three controlled clinical trials, including two trials that showed the drug caused disease remission in about 17-18 percent of the patients. The drug is already approved by the FDA to treat rheumatoid arthritis and psoriatic arthritis.","published_at":1527688905,"content_id":"6c27e4e8-d8d3-33b8-a6a3-b2791390854c","content_url":"https:\/\/finance.yahoo.com\/news\/fda-clears-pfizers-xeljanz-inflammatory-163654202.html","content_published_at":1527698214,"content_time":1527698214,"content_relative_time":2,"reaction_count":0,"vibe_name":"World News","vibe_id":"69f70237-124f-3ea9-acd0-fc922af945e2","content_type":"link","aspect":null}]);